Kohler interview, page-10

Kohler is a bit of a muppet IMO.  He had done very little research for that interview.

Having said that, there is very little analyst coverage/research available on PNV.  This is an opportunity, because surely this is likely to change over the next 6-12 months and you will see increased sp participation by instos and retail.

IMO the comparisons Paul makes with other market-leading Australian multinational healthcare companies is justified.

PNV has a product that is easy to use, high margin and delivers superior patient outcomes than similar competitor products....this is what is called a disruptive product.

PNV/BTM will continue to gain market share and the company is not a one-trick pony.

As sales grow and new products come on line over the coming 2-5+ years, the quarter-on-quarter revenue growth charts are going to look impressive.  This will be reflected in the sp, which I expect will be multiples higher than where it is now.

A very well managed company and a sound investment IMO.